Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bimekizumab - UCB

Drug Profile

Bimekizumab - UCB

Alternative Names: Anti-IL-17-mAb-UCB; Anti-IL-17-monoclonal-antibody-UCB; Anti-interleukin-17-monoclonal-antibody-UCB; bimekizumab-bkzx; BIMZELX; Bimzelx; BKZ; CDP-4940; UCB-4940

Latest Information Update: 27 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator UCB
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erythrodermic psoriasis; Plaque psoriasis; Pustular psoriasis
  • Registered Axial spondyloarthritis; Hidradenitis suppurativa; Psoriatic arthritis
  • Preregistration Ankylosing spondylitis
  • No development reported Psoriasis
  • Discontinued Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 22 May 2024 UCB Pharma plans a phase III BE TOGETHER trial for Plaque Psoriasis (In adolescents, In children) (SC, Injection) in May 2024 (NCT06425549)
  • 30 Apr 2024 Registered for Hidradenitis suppurativa (Treatment-experienced) in European Union, Norway, Iceland, Liechtenstein (SC)
  • 04 Apr 2024 The US FDA accepts sBLA for Bimekizumab 2mL safety syringe and 2mL autoinjector for Hidradenitis suppurativa for review
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top